Inhibition of Cell Growth by Avastin Combined with CTLs in Oral Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2016.08.018

Abstract

Abstract: Objective: To investigate the effect of anti-VEGF monoclonal antibody bevacizumab (Avastin) combined with CTLs induced by tumor antigen-sensitized dendritic cells on inhibiting the growth of oral squamous cell carcinoma (OSCC). Methods: VEGF production in the supernatants of cultured CAL27 and SCC4 were analyzed by enzyme-linked immunoabsorbent assay (ELISA). DCs were generated from human peripheral blood monocytes (PBMCs) and sensitized by SCC4 cell lysates. After that, their phenotypes were analyzed by flow cytometry (FCM), mixed lymphocyte reaction (MLR) for allostimulatory function and IL-12 level was detected by ELISA. DCs loaded with tumor antigen were co-cultured with allogeneic T cells to induce tumor specific cytotoxic T lymphocytes (CTLs). Meanwhile, killing effect of Avastin combined with CTLs to SCC4 in vitro was studied. Results: The level of VEGF secreted by SCC4 was higher than CAL27. Compared with the control group, the expression of CD83, HLA-DR, CD86, CD80 and CD40 on DCs loaded with SCC4 cell lysate, the level of IL-12 and the stimulatory capacity to T cell proliferation were obviously enhanced, but the expression of CD1a was down-regulated. DCs loaded with OSCC antigen increased the proliferation of T lymphocytes. The killing effect of Avastin combined with CTLs was 56.1% to SCC4 and was significantly higher than that of control group (P<0.05). Conclusion: Avastin combined with CTLs induced by tumor-antigen sensitized DCs could inhibit OSCC growth.

Key words: Dendritic cell, VEGF, Bevacizumab, Oral squamous carcinoma cells

CLC Number:

R739.8

JIANG Li-juan, ZHENG Yang, NI Yan-hong, HAN Wei, HUANG Xiao-feng, HU Qin-gang, WANG Zhi-yong. Inhibition of Cell Growth by Avastin Combined with CTLs in Oral Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2016, 32(8): 848-852.

References

[1] 郑家伟,李金忠,钟来平,等.口腔鳞状细胞癌临床流行病学研究现状[J].中国口腔颌面外科, 2007, 5(2)∶83-90
[2] Galluzzi L, Senovilla L, Vacchelli E, et al. trial watch: Dendritic cell-based interventions for cancer therapy [J]. Oncoimmunology, 2012, 1(7)∶1111-1116
[3] Gabrilovich DI, Nadaf S, Corak J, et al. Dendritic cells in antitumor responses. II. Dendritic cells grown from bone marrow precursor, but not mature DC form tumor-bearing mice, are effective antigen carriers in the therapy of established tumors [J]. Cell Immunol,1996,170(1)∶111-119
[4] Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update [J]. Curr Oncol Rep, 2015, 17(6)∶448-451
[5] Cameron D,. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): Primary results of a randomised, phase 3 trial [J]. Lancet Oncol, 2013, 14(10)∶933-942
[6] Zhai H, Zhong W, Yang X, et al. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer [J]. Transl Lung Cancer Res, 2015, 4(1)∶82-93
[7] Flaherty KT. Inhibition of mutated, activated BRAF in metastatic melanoma [J]. N. Engl. J. Med,2010,363(5)∶809-819
[8] Redman JM, Gibney GT, Atkins MB. Advances in immunotherapy for melanoma [J]. BMC medicine, 2016, 14(1)∶20-24
[9] Cimino-Mathews A., Foote J. B., Emens L. A. Immune targeting in breast cancer [J]. Oncology, 2015,29(2)∶375-385
[10] Wang ZY, Shi PH, Huang XF, et al. Peripheral blood dendritic cells and vascular endothelial growth factor in oral squamous cell carcinoma: correlation analysis and in vitro study [J]. Int J Oral Maxillofac Surg, 2010,39(5)∶713-720
[11] Ni YH, Wang ZY, Huang XF, et al. Effect of siRNA-mediated downregulation of VEGF in tca8113 cells on the activity of monocyte-derived dendritic cells [J]. Oncol Lett, 2012,3(6)∶885-892
[12] Su, H. therapeutic antitumor efficacy of tumor-derived autophagosome (DRibble) vaccine on head and neck cancer [J]. Int J Nanomedicine, 2015, 31(9)∶1921-30
[13] Chen Z, Moyanat, Saxena A, et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells [J]. International journal of cancer, 2001, 93(4)∶539-548
[14] tahara H, Lotze M t. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer [J]. Gene therapy, 1995, 2(2)∶96-106
[15] Oyamat, Ran S, Ishida t, et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells [J]. The Journal of Immunology, 1998, 160(3)∶1224-123
[16] Mimura K, Kono K, takahashi A, et al. Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2 [J]. Cancer ImmunolImmunother, 2007, 56(6)∶761-70